The relevance of 'mixed anxiety and depression' as a diagnostic category in clinical practice
- PMID: 27002521
- PMCID: PMC5097109
- DOI: 10.1007/s00406-016-0684-7
The relevance of 'mixed anxiety and depression' as a diagnostic category in clinical practice
Abstract
According to ICD-10 criteria, mixed anxiety and depressive disorder (MADD) is characterized by co-occurring, subsyndromal symptoms of anxiety and depression, severe enough to justify a psychiatric diagnosis, but neither of which are clearly predominant. MADD appears to be very common, particularly in primary care, although prevalence estimates vary, often depending on the diagnostic criteria applied. It has been associated with similarly pronounced distress, impairment of daily living skills, and reduced health-related quality of life as fully syndromal depression and anxiety. Although about half of the patients affected remit within a year, non-remitting patients are at a high risk of transition to a fully syndromal psychiatric disorder. The validity and clinical usefulness of MADD as a diagnostic category are under debate. It has not been included in the recently released DSM-5 since the proposed diagnostic criteria turned out to be not sufficiently reliable. Moreover, reviewers have disputed the justification of MADD based on divergent results regarding its prevalence and course, diagnostic stability over time, and nosological inconsistencies between subthreshold and threshold presentations of anxiety and depressive disorders. We review the evidence in favor and against MADD and argue that it should be included into classification systems as a diagnostic category because it may enable patients to gain access to appropriate treatment early. This may help to reduce patients' distress, prevent exacerbation to a more serious psychiatric disorder, and ultimately reduce the societal costs of this very common condition.
Keywords: Classification; Mixed anxiety and depression; Psychiatric disorder; Subthreshold anxiety; Subthreshold depression.
Conflict of interest statement
Prof. Dr. Hans-Jürgen Möller has received grant/research support, consulting fees, and honoraria within the last years from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck, MSD, Novartis, Organon, Otsuka, Pfizer, Schwabe, Sepracor, Servier, and Wyeth. Prof. Dr. Bandelow has received consultant’s fees from Lundbeck, Otsuka, and Pfizer and honoraria for lecturing at continuing medical education events from Glaxo, Janssen, Lundbeck, Meiji-Seika, Pfizer, and Servier. Prof. Dr. Hans-Peter Volz has served as a consultant or on advisory boards for AstraZeneca, Lundbeck, Pfizer, Schwabe, Otsuka, Merz, Lilly, Janssen, Neuraxpharm, Steigerwald and has served on speakers’ bureaus for AstraZeneca, Eli Lilly, Lundbeck, Schwabe, Janssen, Merz, Steigerwald, Otsuka, Neuraxpharm, Steigerwald, Bristol-Myers Squibb, Tromssdorff. Prof. Dr. Utako Birgit Barnikol has no disclosures and no conflicts of interests to declare. Prof. Dr. Erich Seifritz’s work has been funded by the University of Zürich and the Swiss National Science Foundation. He has received compensation as a member of the scientific advisory boards of Lundbeck, Otsuka, Janssen, Eli Lilly, Schwabe, and Takeda. He gave scientific talks in symposia financed by Eli Lilly, Astra Zeneca, Lundbeck, Schwabe, Opopharma, and Janssen. Prof. Dr. Siegfried Kasper has received grant/research support from Eli Lilly, GlaxoSmithKline, Lundbeck, Pfizer, and Servier; he has served as a consultant or on advisory boards for AstraZeneca, Eli Lilly, GlaxoSmithKline, Janssen, Lundbeck, Novartis, Pfizer, Schwabe, and Servier; he has served on speakers’ bureaus for Angelini, AOP Orphan Pharmaceuticals AG, AstraZeneca, Eli Lilly, Janssen, Krka Pharma, Lundbeck, Neuraxpharm, Pfizer, Pierre Fabre, Schwabe, Servier.
Similar articles
-
Mixed anxiety depression should not be included in DSM-5.J Nerv Ment Dis. 2012 Jun;200(6):495-8. doi: 10.1097/NMD.0b013e318257c4c9. J Nerv Ment Dis. 2012. PMID: 22652614
-
Who is MADD? Mixed anxiety depressive disorder in the general population.J Affect Disord. 2010 Feb;121(1-2):180-3. doi: 10.1016/j.jad.2009.06.008. Epub 2009 Jul 4. J Affect Disord. 2010. PMID: 19577307
-
Letter to the Editor: CONVERGENCES AND DIVERGENCES IN THE ICD-11 VS. DSM-5 CLASSIFICATION OF MOOD DISORDERS.Turk Psikiyatri Derg. 2021;32(4):293-295. doi: 10.5080/u26899. Turk Psikiyatri Derg. 2021. PMID: 34964106 English, Turkish.
-
Mixed anxiety and depression: should it be included in DSM-IV?J Clin Psychiatry. 1993 May;54 Suppl:4-7; discussion 17-20. J Clin Psychiatry. 1993. PMID: 8509357 Review.
-
Depression and anxiety: implications for nosology, course, and treatment.J Clin Psychiatry. 1997;58 Suppl 8:3-5. J Clin Psychiatry. 1997. PMID: 9236728 Review.
Cited by
-
Course trajectories of anxiety disorders: Results from a 6-year follow-up in a general population study.Aust N Z J Psychiatry. 2021 Nov;55(11):1049-1057. doi: 10.1177/00048674211009625. Epub 2021 Apr 22. Aust N Z J Psychiatry. 2021. PMID: 33887978 Free PMC article.
-
Is There Evidence for the Specificity of Closed-Loop Brain Training in the Treatment of Internalizing Disorders? A Systematic Review.Front Neurosci. 2022 Mar 10;16:821136. doi: 10.3389/fnins.2022.821136. eCollection 2022. Front Neurosci. 2022. PMID: 35360168 Free PMC article.
-
Intervention in Neuropsychiatric Disorders by Suppressing Inflammatory and Oxidative Stress Signal and Exploration of In Silico Studies for Potential Lead Compounds from Holigarna caustica (Dennst.) Oken leaves.Biomolecules. 2020 Apr 6;10(4):561. doi: 10.3390/biom10040561. Biomolecules. 2020. PMID: 32268590 Free PMC article.
-
Therapy resistance/chronicity, their determinants and potential solutions.Eur Arch Psychiatry Clin Neurosci. 2020 Feb;270(1):1-2. doi: 10.1007/s00406-020-01101-6. Eur Arch Psychiatry Clin Neurosci. 2020. PMID: 32055944 Free PMC article. No abstract available.
-
Psychological Profiles and Clinical Clusters of Patients Diagnosed With Functional Neurological Disorder.Front Neurol. 2020 Oct 15;11:580267. doi: 10.3389/fneur.2020.580267. eCollection 2020. Front Neurol. 2020. PMID: 33178122 Free PMC article.
References
-
- Angst J, Merikangas K (1997) The depressive spectrum: diagnostic classification and course. J Affect Disord 45 (1–2):31–39; discussion 39-40 - PubMed
-
- Tiller JWG. Depression and anxiety. MJA Open. 2012;1(Suppl 4):28–32.
-
- World Health Organization . International statistical classification of diseases and related health problems, tenth revision (ICD-10) Geneva: World Health Organization; 1992.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical